600518 Kangmei Pharmaceutical
- 2.01
- +0.03+1.52%
About Kangmei Pharmaceutical Company
The company was founded in 1997 and listed on the Shanghai Stock Exchange in 2001; it also introduced state-owned capital and powerful industry investors in 2021, becoming an enterprise actually controlled by Guangdong Shennong Enterprise Management Partnership (Limited Partnership). Adhering to the business philosophy of “New Kangmei, Health and Beauty”, the company insists on focusing on the main business and continuing to consolidate the layout of the entire traditional Chinese medicine industry chain; with traditional Chinese medicine tablets as the core and smart pharmacy as the starting point, the company promotes the implementation of five major projects, including the national demonstration of smart pharmacy standardization, and comprehensively builds an “big health+big platform+big data+big service” system to further build an influential “smart +” health industry enterprise with accurate service for the entire traditional Chinese medicine industry chain. The company takes the production and sales of Chinese medicine tablets as the core, and implements an integrated operation model for the entire traditional Chinese medicine industry chain. The business system covers upstream cultivation of authentic Chinese herbal medicines, fresh processing and resource integration; midstream Chinese herbal medicine specialty market management, production and sales of Chinese herbal medicines, health food, chemicals and medical devices; and a comprehensive multi-level marketing network integrating downstream medical institution resources, smart pharmacies, OTC retail, chain pharmacies, direct sales, pharmaceutical e-commerce, and mobile medical care. The company's main products include Chinese medicine tablets, proprietary Chinese medicines, chemicals, health food and food. Corporate honors: “Jieyang City Caring Donor Enterprise to Fight COVID-19”, the company became one of the top 2000 global enterprises, the top 500 Chinese enterprises, the most valuable investment listed company, China's 50 most respected listed companies, China's top ten pharmaceutical industry, the top ten pharmaceutical companies with the highest brand competitiveness in China, the top 100 enterprises in Guangdong tax, and the “2023 National Intellectual Property Demonstration Enterprise” honorary medal. It is the only enterprise in Jieyang City to receive the “National Intellectual Property Demonstration Enterprise” award in 2023.
Company Profile
Company Executives
- Name
- Position
- Salary
- zhijian lai
- Chairman, Directors, Strategy Committee Convener, Remuneration and Assessment Committee Members
- 1.50M
- guowei liu
- Directors, General Manager, Strategy Committee Members, Nomination Committee Members
- 1.50M
- huayue xia
- Directors, Member of the Strategy Committee
- --
- miaoshuang fang
- Directors
- --
- jun liang
- Directors
- --
- qi mi
- Directors, Audit Committee Members
- 1.08M
- qing ceng
- Independent Directors, Remuneration and Assessment Committee Members, Nomination Committee Convener
- 120.00K
- xiaoping lai
- Independent Directors, Audit Committee Members, Remuneration and Assessment Committee Convener
- 120.00K
- tao luo
- Independent Directors, Nomination Committee Members, Audit Committee Convener
- 120.00K
- yunfeng zhou
- Board Secretary, Deputy General Manager
- 1.35M
- min li
- Securities Affairs Representative
- --
- yanzhu gao
- Chairman of the Supervisory Board, Auditors
- 1.13M
- tong wang
- Auditors
- 621.80K
- zezheng he
- Deputy General Manager
- 1.13M
- xinquan liu
- Deputy General Manager
- 1.20M
- guibo gong
- Deputy General Manager, Chief Financial Officer
- 1.35M
- guoxiong ou
- Deputy General Manager
- 1.20M
- qiyun chen
- Deputy General Manager
- 1.20M
- zebin li
- Assistant to the General Manager
- 1.05M
- lei chen
- Assistant to the General Manager
- 774.90K
- libing huang
- Assistant to the General Manager
- --
- longtao huang
- Employee Supervisors
- 653.80K
Analysis
Price Target
No Data
No Data